SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study.
Maya MosheAnna DauntBarnaby FlowerBryony SimmonsJonathan C BrownRebecca FriseRebecca PennRuthiran KugathasanClaire PetersenHelen StockmannDeborah AshbySteven RileyChristina AtchisonGraham P TaylorSutha SatkunarajahLenny NaarRobert KlaberAnjna BadhanCarolina RosadasFederica MarchesinNatalia FernandezMacià Sureda-VivesHannah CheesemanJessica O'HaraRobin ShattockGianluca FontanaScott J C PallettMichael RaymentRachael JonesLuke S P MooreHutan AshrafianPeter CherapanovRichard TedderMyra McClureHelen WardAra DarziPaul ElliottGraham S CookeWendy S Barclaynull nullPublished in: BMJ (Clinical research ed.) (2021)
One new LFIA was identified with clinical performance suitable for potential inclusion in seroprevalence studies. However, none of the LFIAs tested had clearly superior performance to the LFIA currently used in React 2 seroprevalence surveys, and none showed sufficient sensitivity and specificity to be considered for routine clinical use.